Financial Advocates Investment Management Grows Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Financial Advocates Investment Management raised its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 28.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the company’s stock after buying an additional 11,000 shares during the quarter. Financial Advocates Investment Management owned about 0.05% of Aquestive Therapeutics worth $178,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Aquestive Therapeutics by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after buying an additional 90,543 shares in the last quarter. State Street Corp grew its holdings in Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after buying an additional 512,682 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Aquestive Therapeutics by 6.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock valued at $3,505,000 after buying an additional 61,200 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Aquestive Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock valued at $1,014,000 after buying an additional 9,268 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $995,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $2.99 on Tuesday. Aquestive Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $6.23. The firm has a market capitalization of $272.62 million, a P/E ratio of -6.64 and a beta of 2.67. The stock has a 50 day moving average price of $3.44 and a 200 day moving average price of $4.21.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AQST shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective for the company. Finally, Leerink Partners raised their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.